Pharmaceutical Industry

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are expanding their strategic partnership, which began in 2023, with a series of substantial investments aimed at bolstering U.S. pharmaceutical manufacturing. The collaboration, marked by a $750 million investment, focuses on increasing the production of Lilly’s KwikPen®, a

Samsung Biologics reports $262M manufacturing deal running through 2033

Samsung Biologics disclosed a $262 million manufacturing deal with an undisclosed European pharmaceutical company that runs through 2033.

Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte estimated top biopharma firms could capture $5-7B in AI value. McKinsey and ISPE material show why timelines and validation still lag.

Biopharma's $300 Billion Patent Cliff Is Driving Its Strongest M&A Cycle Since the Pre-Pandemic Peak

More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences initiates what it calls the first Phase I trial of an AI-designed oral drug formulation, approved by the UK's MHRA.